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Characterization of Metronidazole- and Vancomycin-Resistant Clinical Isolates of 
Clostridium difficile 
Chioma Odo, MS. 
Supervisory Professor: Charles Darkoh, Ph.D. 
ABSTRACT 
The incidence of C. difficile infections (CDI) has been increasing at an alarming rate. This 
was precipitated by the emergence of strains with increased virulence, disease severity, 
and high recurrence rates. These strains also exhibit high propensity for resistance to 
antibiotics such as fluoroquinolones and beta lactams, which has made the treatment of 
CDI very challenging. Currently, metronidazole and vancomycin are the most commonly 
used drugs for the treatment of primary CDI. Metronidazole is used for the treatment of 
mild to non-severe cases of CDI while vancomycin is reserved for severe CDI cases. In 
25-30% of the patients treated with these antibiotics, the infection may recur, and this 
further complicates CDI treatment. Because C. difficile strains have an intrinsic ability to 
resist multiple antibiotics, it was hypothesized that there may be strains with high 
resistance to metronidazole and vancomycin circulating in the patient population.  To 
investigate this hypothesis, 536 clinical CDI stool samples obtained from patients who 
presented with diarrhea at St. Luke’s Episcopal Hospital at the Texas Medical Center 
Houston, Texas, Kenyatta National Hospital, Nairobi, and Kisii Teaching and Referral 
Hospital, Kisii, Kenya were screened for resistant C. difficile strains. The stool samples 
were analyzed on C. difficile-specific differential medium containing either metronidazole 
(8 µg/ml) or vancomycin (4 µg/ml). These are concentrations designated by the Clinical 
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and Laboratory Standards Institute to be the resistant breakpoint for each of the 
antibiotics. Stools that grew resistant colonies were identified and colonies were selected 
for further analysis. The minimum inhibitory concentration (MIC) of the isolates was 
determined by E-test and broth microdilution. The results showed that 33.1% (145/438) 
of the CDI patients from Texas had C. difficile strains in their stools that were resistant to 
both metronidazole and vancomycin. Remarkably, 93.9% of the CDI patient stools from 
Kenya had both metronidazole- and vancomycin-resistant C. difficile strains. The resistant 
strains from both patient populations also exhibit high level of tolerance for these 
antibiotics that far exceed the previously reported MICs (˃1024 µg/ml compared to 256 
µg/ml for metronidazole and >1024 µg/ml compared to 16 µg/ml for vancomycin). All of 
the vancomycin-resistant strains isolated from the patients in both populations had the 
homologue of vanA gene, which has been shown to confer a high degree of vancomycin 
resistance in Gram-positive bacteria. Together, the results demonstrate high prevalence 
of metronidazole- and vancomycin-resistant C. difficile strains circulating in the patient 
populations from Texas and Kenya. The spread of C. difficile strains that are resistant to 
these two antibiotics of last resort may have serious public health implications and 
underscores the urgent need for a more in-depth analysis of the circulating resistant 
strains to help inform clinical decisions. 
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INTRODUCTION 
Epidemiology of Clostridium difficile Infections 
Clostridium difficile is a multidrug-resistant, spore forming, Gram-positive 
anaerobic pathogen. It is the most common cause of hospital-acquired and healthcare-
associated infectious diarrhea (1). Broad spectrum antibiotics use is the most common 
risk factor for Clostridium difficile infection (CDI), as it alters colonization resistance, 
thereby rendering the microbiota susceptible to C. difficile colonization and infection (2). 
Clinical symptoms of CDI range from mild to severe diarrhea, pseudomembranous 
colitis, toxin megacolon, septic shock or even death (3). The Centers for Disease 
Control and Prevention (CDC) has classified C. difficile as an urgent threat with 
approximately 453,000 reported cases, 29,000 deaths, and $1.1 to 7 billion in treatment 
costs annually in the US (4).  Recently, the incidence of CDI has exceeded that of 
methicillin-resistant Staphylococcus aureus (MRSA) in the community hospitals (5). 
There is an increased report of CDI among the young under 18 and also in communities 
outside the hospital, such as assisted care facilities for the elderly.  
The emergence of C. difficile strains with resistance to multiple antibiotics, 
especially the most prominent hyper-virulent strain ribotype (RT) 027, has added 
another complication to the treatment of CDI (6). (RT) 027, which is commonly found in 
the US, Europe and Canada is completely intractable to traditional treatment with 
increased recurrence and mortality rate (6). The emergence is associated with 
fluoroquinolone exposure (6). C. difficile RT027, also known as fluoroquinolone-
resistant (FQR) C. difficile, is the most common cause of outbreaks in North America 
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and the UK (with more than 40% of the reported cases in the UK) and it was recently 
reported to be common in other parts of Europe and Australia (7). 
 
Clostridium difficile Pathogenesis 
C. difficile is spread through ingestion of its spores, which tolerates both stomach 
acidic and harsh environmental conditions.  Under favorable conditions, such as the 
presence of bile acids in the small intestine, the ingested spores germinate into 
vegetative cells that colonize the large intestine following disruption of normal 
microbiota by antibiotic therapy (15). 
Spore germination is initiated when a receptor within the inner membrane of the 
spore interacts with a germinant such as ions, sugar, nucleotides, bile acids or 
surfactants (48). When the spore receptor senses or recognizes a germinant, it triggers 
an irreversible spore germination process which leads to the release of Ca2+-dipicolinic 
acid, water uptake, spore cortex degradation, and outgrowth of the vegetative cells and 
under appropriate conditions, produce toxins that cause disease (41). 
The vegetative form of C. difficile thrives in the lumen of the large intestine and 
produces two major toxins: toxins A (an enterotoxin) and B (a cytotoxin) (15). These two 
major virulence factors are encoded by the tcdA and tcdB genes, respectively, and are 
located within 19.6 kb of the pathogenicity locus (PaLoc) in the genome (Fig.1). They are 
members of large clostridial toxins, a family of toxins that modifies GTPases (16, 95, 96). 
Also found in the pathogenicity locus is tcdC, which negatively regulates expression of 
tcdA and tcdB. The tcdE gene, encodes a holin (essential for the extracellular release of 
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toxins A and B) and tcdR, encodes a sigma factor that is required for toxin A and B 
expression. The PaLoc, located at the same site in all toxin-producing strains, can be 
horizontally transferred to non-toxin producing strains, however, it is not intrinsically 
mobile (38).  
The amino acid sequences of TcdA and TcdB are 44% identical and 66% similar 
and share a common structure (95). The C-terminus has a high degree of sequence 
diversity. Both toxins have a similar three-dimensional structure and a similar mode of 
entry into host cells (38). They both have a “pincher-like” head delivery domain, a 
receptor-binding domain, also known as the long tail domain at the C-terminus, and a 
short inner tailed (52) glucosyltransferase domain at the N-terminus. Generally, both 
toxins share similar enzymatic activities, as well as multi-modular domain structure, 
described as the ABCD model (A: biological activity, B: binding, C: cutting and D: 
delivery) (Fig. 1B) (38, 52). Region A, which is the short tail region, is located at the N-
terminus and it is the site of biological activity of the toxins. They contain the 63 kDa 
glucosyltransferase domain (GTD) that modifies the small GTPases, which regulates 
the host cytoskeleton (38, 42). Region B, the long tail region, is located at the C-
terminus and consists of combined repeated oligopeptides (CROPs) that form the 
receptor binding domain (RBD). The RBD binds to receptors on the host cell and 
becomes internalized through receptor-mediated endocytosis. The region C contains 
the cysteine protease domain (CPD), which is responsible for autoprocessing of the 
glucosyltransferase domain, endocytosis, and translocation of the toxin into the cytosol 
of target cells. Also contained in region C of both TcdA and TcdB is a three-helix bundle 
region, conserved in both toxins and located at the junction of GTD-CPD region (39, 42, 
4 
 
52).  The D region contains the delivery hydrophobic domain, which is responsible for 
translocation into the cytosol and binding to the GTPase of target cells in the host 
(38). Also, part of the D domain is the small globular sub-domain (SGD) and an 
elongated hydrophobic helical stretch containing four α-helices (38, 52).  
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Figure 9: (A) The schematic representation of the components of the C. difficile 
toxin pathogenicity locus (PaLoc) and (B) the multi-modular domain structure of 
TcdA and TcdB.  The PaLoc comprises of tcdR, tcdB, tcdE, tcdA, and tcdC genes. The 
tcdR is a 555 bp, positive regulator that encodes an alternative RNA polymerase sigma 
factor that regulates tcdA and tcdB expression. tcdB is 7101 bp and encodes toxin B. 
The 501 bp tcdE encodes a putative holing domain/protein, which has been suggested 
to be responsible for extracellular release of both toxin A and B (38). The tcdA (8133 
bp) encodes toxin A, whereas the 699 bp tcdC encodes a negative regulator of toxin A 
and B (38). The ABCD model (A, biological activity; B, binding; C, cutting; D, delivery) 
domain structure of the two toxins contains the A and C domains, which corresponds to 
the N-terminal glucosyltransferase domain (GTD) in red and cysteine protease domain 
(CPD) in cyan, followed by the three-helix domain 3HB in blue (38). The D domain 
corresponds to the delivery hydrophobic domain (DD) (in yellow), which contains the 
small globular domain (SGD).  The B domain (in pink), corresponds to the receptor 
binding domain (RBD) (38). 
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The mechanism of action of toxin A and B on the mammalian target cells involves 
receptor-mediated endocytosis, which leads to protein translocation out of the 
endosome. Translocation and release of the toxins in the host cell triggers auto-
proteolytic processing and subsequently monoglucosylation of host Rho and Ras 
proteins (39, 97, 98). The highly repetitive C-terminal domain of the toxin binds to the 
target cell and is internalized through endocytosis (52). The N-terminal translocation 
across the membrane is facilitated by the low pH of the endosome. The delivery 
domain, which is the central region, has hydrophobic residues that changes its 
conformation at low pH leading to membrane insertion and pore formation (39, 41, 52).  
The N-terminal glucosyltransferase is translocated through the pore and is released into 
the cytosol of the target cell to disrupt the small GTPases, such as Rho and Ras 
proteins. The Rho and Ras proteins are important in maintaining the integrity of the 
cytoskeleton. Rho monoglucosylation results in its inactivation and loss of ability to 
polymerize actin filament leading to deregulation of the actin cytoskeleton and loss of 
cell-to-cell contact at the tight junctions due to signal disruption (32, 97). This leads to 
the release of cytokines from mast cells resulting in fluid secretion, intestinal 
inflammation, and apoptosis (16).  
Another putative virulence factor, CDT binary toxin, also contributes to C. difficile 
pathogenesis (32). This toxin disrupts the cytoskeleton and forms microtubule-based 
projections that facilitate C. difficile adherence to the surface of epithelial cells.  About 
35% of C. difficile strains secret the binary toxin, which is encoded by cdtA and cdtB 
(35). There are two domains: CDTa, the biologically active ADP-ribosyltransferase that 
modifies actin and CDTb, the binding component, which is involved in binding and 
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transportation of the enzymatic component into the cytosol.  ADP-ribosyltransferase 
modifies monomeric G-actin and inhibits its polymerization as ADPribosylated actin 
attaches to the barbed end of the actin filament. This inhibits elongation and formation 
of F-actin leading to cell rounding and death. (34, 36). 
 
Treatment of C. difficile Infections 
Antimicrobial agents play an important role in CDI as they are involved in both induction 
and resolution (4). Third generation antibiotics cephalosporins and clindamycin were 
previously used for treatment of CDI, but they are currently associated with promoting 
risk of CDI (4). CDI treatment depends on the disease classification. CDI can be 
classified as non-severe to mild, recurrent, severe or complicated, and the type of 
treatment depends on the disease severity. Metronidazole is commonly prescribed for 
non-severe to mild cases, whereas vancomycin is usually reserved for severe cases 
(10). Other antibiotics, such as rifaximin and teicoplanin, are also used (54). Rifaximin is 
a non-absorbable oral antibiotic usually prescribed for first and recurrent CDI. 
Teicoplanin, a glycopeptide, is similar to vancomycin but is not approved in the United 
States (44). Metronidazole is neurotoxic and so is not used for long-term or recurrent 
treatment. Vancomycin is usually reserved for severe cases of CDI. Fidaxomicin, a 
novel macrocyclic antibiotic, is now being considered as a vancomycin substitute (44, 
45).  
In addition to treating severe CDI, vancomycin is active against both metronidazole-
resistant C. difficile and epidemic strains with high metronidazole tolerance.  Second 
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and subsequent recurrences of CDI are usually treated with tapered and/or pulsed 
doses of vancomycin (10). In severe cases of CDI, vancomycin and metronidazole can 
be administered through different routes. Vancomycin is usually given directly into the 
colon, though oral and rectal delivery are also recommended.  Failure of treatment is 
believed to stem from a dynamic ileus (paralysis of the small bowel), which may prevent 
the oral vancomycin from reaching the colon and thus be ineffective. Therefore, 
vancomycin is injected directly into the colon (75, 76). Combination of intravenous 
metronidazole with intracolonic vancomycin administered by nasogastric tube is 
recommended by the European Society of Clinical Microbiology and Infectious Diseases 
(ESCMID) guideline to be used in severe cases where oral therapy is not effective (3, 
46). Vancomycin is recommended by Infectious Disease Society of America for 
suspected severe cases. A study that evaluated the appropriateness of CDI empiric 
treatment showed that many CDI patients receive inappropriate empirical treatment 
without meeting the criteria for severe CDI. Half of this empirical treatment is reportedly 
dispensed without confirmation. Therefore, patients are often treated inappropriately 
(15).  
Metronidazole- and vancomycin-induced collateral damage of the microbiota has 
been found to be associated with a high incidence of CDI recurrence following 
conventional treatment (14). Although most patients respond well to treatment and have 
their standard metronidazole and/or vancomycin antibiotic therapy discontinued after 10 
to 14 days, some patients have symptoms that persist or recur after treatment. The rate 
of CDI recurrence is between 20 to 35%, and the rate of recurrence increases with each 
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subsequent episode (68). One of the identified significant risk factors for relapse is an 
initial infection with the BI/NAP1/027 epidemic clone (56). 
The recommended treatment following recurrence of CDI is not straight forward, 
as metronidazole is not appropriate for prolonged administration (53) and there has also 
been a gradual increase of the C. difficile strain with resistance to metronidazole (28, 
30). Using the Clinical laboratory standard institute (CLSI) breakpoints, 8% of C. difficile 
clinical isolates were found to be resistant to vancomycin in Iran (53) based on a report 
of increased resistance and reduced sensitivity to both metronidazole and vancomycin 
(54, 55). Treatment failures with these last resort antibiotics is a result of C. difficile 
developing resistance to these antimicrobial agents (54).   
 
Antimicrobial Resistance in C. difficile 
Antimicrobial resistance is the ability of microorganisms (bacteria, fungi, viruses, 
and parasites) to resist the effects of antimicrobial drugs (antibiotics, antifungals, 
antivirals, antimalarials, and antihelmintics) (58, 59). Pathogens that are able to resist 
multiple antimicrobials are often referred to as “superbugs”. Antibiotic resistance has 
become a global threat. In the United States alone, about 2 million people become 
infected with bacteria that are resistant to antimicrobials designed to kill them and about 
23,000 patients die as a result of antimicrobial-resistant bacteria (27). New forms of 
resistance can easily spread across continents with significant speed. The mortality rate 
due to antimicrobial resistance is expected to reach about 10 million patients by the 
year 2050, with an estimated global cost of $100 trillion (40).  The most important cause 
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of antimicrobial resistance is the overuse of antibiotics, which is also the leading risk 
factor for CDI (4).  
C. difficile is resistant to multiple antibiotics (14). Antibiotic resistance is a 
significant factor in CDI dissemination among some hospitalized, elderly, and 
immunocompromised patients (14). C. difficile is currently resistant to the following 
antibiotics previously used for treatment: penicillin, clindamycin, erythromycin, 
cephalosporins, fluoroquinolones and tetracycline (27, 28). Clindamycin was identified 
as the highest risk factor in 1970, and was replaced by cephalosporin in the 80s, and 
most recently fluoroquinolones (6). Studies of antimicrobial resistance of different C. 
difficile isolates in North America, Europe, and Asia show that clindamycin resistance 
ranges from 15 to 97% (28). The C. difficile strains most reported to be resistant to 
different antibiotics in different countries and continents are as follows: (i) 30% of 
ribotype 027 strains are resistant to clindamycin, moxifloxacin, and rifampin in North 
America; (ii) in the United States, about 98% of ribotype 027 strains are resistant to 
moxifloxacin; and (iii) in the Netherlands, ribotype 078, (another hypervirulent strain) is 
resistant to ciprofloxacin, erythromycin, imipenem, and moxifloxacin (29, 31).  
The hypervirulent BI/NAP1/027, also known as FQ-resistant C. difficile strain, is 
characterized by efficient sporulation, high toxin production, and enhanced cytotoxicity 
(57). Spore production in C. difficile is an important mechanism of persistence that 
facilitates resistance to antibiotics and to the host immune system (28). 
Although metronidazole and vancomycin remain the most effective mode of 
treatment for most CDI cases, approximately 25% of patients treated with either 
antibiotics can recur typically within 4 weeks of completing the primary therapy (15). 
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Currently, C. difficile isolates with increased resistant to metronidazole and vancomycin 
are increasing (30).  
 
 Metronidazole Mode of Action  
Metronidazole (Fig. 2) causes its antimicrobial action by damaging bacterial DNA 
through reduction of the nitro group into cytotoxic nitrosoimidazole and nitroradical 
anion by thioredoxin reductase (17, 20). The most important system involved in 
metronidazole activation is the pyruvate-ferredoxin/ flavodoxin oxidoreductase (PFOR) 
system, which works in concert with ferredoxin and glycerol-3-phosphate hydrogenase 
to reductively activate metronidazole directly (19). The nitroradical anion reduces O2 to 
generate reactive oxygen species, which is highly deleterious to the cell. 
Nitrosoimidazole on the other hand, forms an adduct when reacted with non-protein 
thiols or proteins. Adduct formation causes both depletion of non-protein thiols and 
modification of metronidazole’s target proteins: purine nucleoside phosphorylase (PNP), 
thioredoxin, thioredoxin reductase, and superoxide dismutase (SOD) leaving the cell 
vulnerable to oxidative stress and eventually death (19, 20). 
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Figure 10: Mechanism of action of metronidazole. Under anaerobic conditions, 
metronidazole is reduced to nitroradical anion or nitrosoimidazole by thioredoxin 
reductase. The nitroradical anion formed reduces O2 and thereby generates reactive 
oxygen species causing oxidative damage to the cell. Nitrosoimidazole in the presence 
of non-protein thiols forms protein adducts, which modify thioredoxin reductase (TrxR), 
thioredoxin (Trx), superoxide dismutase (SOD), metronidazole target protein 1 (Mtp1), 
and purine nucleoside phosphorylase (PNP), and eventually causes to cell death (17). 
 
13 
 
The Proposed Mechanisms of Metronidazole Resistance in C. difficile.  
The exact mechanism of metronidazole resistance has not yet been established in C. 
difficile.  The nimA-J gene cluster is associated with metronidazole-resistance in 
different genera of both Gram-positive and Gram-negative anaerobic bacteria, 
including Bacteroides species (80). The nimA-J genes encode an alternative reductase, 
which convert nitroimidazoles to a stable and non-cytotoxic amine derivative to 
circumvent the toxic species that causes DNA breakage (4, 17, 80).  However, 
homologs of the nim genes are not present in the C. difficile genome.  
Comparative whole genome sequencing analysis of a stable metronidazole-resistant 
(RT) 027 strain, a clone resistant to metronidazole and became susceptible upon 
freeze-thaw (63) revealed the following mutations: (i) mutations within the sporulation 
gene (spo0A) and germination (cspC) loci;(ii) mutations in the ferric uptake regulator 
(fur), a putative nitroreductase gene; and (iii) a mutation in the coproporphyrinogen III 
oxidase gene (hemN) (60, 61, 62, 4). In another study, a proteomic analysis of a similar 
(RT) 027 strain revealed no evidence of association of deficiencies in the PFOR system. 
However, an increase in production of the ferric uptake regulator protein (a central 
regulator of iron homeostasis in bacteria) was observed in the metronidazole-resistant 
(RT) 027 strain (4, 19). 
The proposed mechanism of metronidazole resistance is complex (17) (Fig. 3) and 
manifests as either a reduced rate of internal concentration of metronidazole due to 
increased efflux or by a reduced rate of metronidazole reductive activation by altering 
pyruvate fermentation. Other mechanisms that have been suggested to be involved are 
reduced iron transport and increased DNA repair efficiency (19), reduced rate of 
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glucose uptake, which alters pyruvate fermentation leading to downregulation of PFOR 
and upregulation of lactic acid dehydrogenase (17, 51). During fermentation, PFOR 
reduces pyruvate to acetyl-CoA and CO2 releasing electrons. The electrons flow 
through PFOR to reduce ferredoxin then proceed to hydrogenase, which is a low redox 
carrier (17). It was originally proposed that PFOR in collaboration with ferredoxin were 
the only proteins with adequately low redox potential to actively reduce metronidazole in 
anaerobic bacteria, but it was later discovered that effectors with high negative midpoint 
redox capacities, such as flavodoxin and glycerol-3-phosphate hydrogenase, were 
equally able to reductively activate metronidazole directly in C. pasteurianum (17). This 
process is inhibited in metronidazole-resistant isolates, as deficiencies in pyruvate 
dehydrogenase activity is consistent with changes in the end products of glucose 
metabolism (64).  
 Other proposed mechanisms of resistance include overexpression of efflux pump 
genes, which have been shown to be associated with metronidazole resistance in other 
bacteria (65). In Bacteriodes species, decrease in metronidazole uptake because of 
increased efflux are facilitated by an over active multidrug efflux pump system and this 
results in a reduced subsequent reductive activation (19, 65).  Also, inactivation of the 
recA gene, which is required for generalized DNA repair and recombination, improved 
susceptibility of H. pylori to metronidazole and expression of a cloned recA gene from a 
metronidazole-resistant strain reportedly increased the level of metronidazole resistance 
in E. coli (66).  Another mechanism involved in resistance is the mutation of the ferrous 
iron transporter FeoAB, which inhibits iron uptake (17, 18). 
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Figure 11: Mechanisms of metronidazole resistance. The mechanisms of 
metronidazole resistance are complex. Loss of function in various enzymes results in 
reduced susceptibility to metronidazole. The enzymes include pyruvate: ferredoxin 
oxidoreductase (PFOR), lactate dehydrogenase (LDH), hydrogenase (HYD), DNA 
helicase (RecQ), and DNA repair effectors recombinase A (RecA) (18, 19).  The 
Bacteroides multidrug efflux pump system (BME) also facilitates metronidazole efflux. 
Oxygen-insensitive nitroreductase (NfsA) and the nim genes (NIM) reductively 
inactivate the nitro group attached to the amino derivative of metronidazole and reduces 
it into a stable amino derivative. Crosses (X) indicate reduced activity or uptake 
whereas the red arrows indicate the change expression that confers metronidazole 
resistance (18). 
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Peptidoglycan Biosynthesis and Mechanism of Action of Vancomycin 
There are three stages involved in the biosynthesis of cell wall polymers (26) 
(Fig. 4). The first stage is the precursor synthesis in the cytoplasm, which involves the 
conversion of L-alanine to D-alanine (D-Ala) by the enzyme racemase and then joining 
of two molecules of D-Ala by D-alanine-D-alanine ligase (Ddl) to form dipeptide D-Ala-
D-Ala (26). The second stage involves the formation of the subunit bound to mobile lipid 
undecaprenylphosphate. Uracil diphosphate–N-acetylmuramyl-tripeptide is added to the 
dipeptide D-Ala-D-Ala to form uracil diphosphate–N-acetylmuramyl-pentapeptide. Uracil 
diphosphate–N-acetylmuramyl-pentapeptide is bound to the mobile lipid 
undecaprenylphosphate for translocation to the outer surface of the membrane. The 
third and the final stage is transglycosylation and transpeptidation, in which N-
acetylmuramyl-pentapeptide is attached to the nascent glycan chain by 
transglycosylation and finally cross bridge formation by transpeptidation (24, 26). 
Vancomycin binds to the C-terminus of D-alanine-D-alanine during cell wall 
peptidoglycan biosynthesis to block transglycosylation and transpeptidation reactions 
(18, 25).  It interferes with the late stage of peptidoglycan assembly. This is evident in 
the assembly of cell wall precursor UDP-MurNAc-pentapeptide in the cytoplasm (26). 
Vancomycin interaction with the precursor takes place only after translocation to the 
outer membrane, since vancomycin cannot penetrate the cell into the cytoplasm.  
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 Figure 12: Peptidoglycan biosynthesis and mechanism of action of vancomycin. 
Vancomycin binds to the C-terminal D-Ala–D-ala of peptidoglycan precursors 
preventing the function of transglycosylases, transpeptidases, and the 
carboxypeptidases.  D-Ala-D-Ala ligase (Ddl) joins the two D-alanines and MurF, the 
pentapeptide synthetase flips the precursor (UDP N-acetylmuramyl-pentapetide and N-
acetyglucosamine) to get attachment to the growing chain of peptidoglycan precursor 
(26). 
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Vancomycin Resistance Mechanisms in Gram-Positive Bacteria 
The mechanism of acquired vancomycin resistance is well established in 
Staphylococcus aureus and Enterococcus spp. However, the mechanism of 
vancomycin-resistance in C. difficile is not known. Vancomycin is not target enzyme-
specific and does not interact with enzymes responsible for cell wall biosynthesis, but 
rather is substrate-specific (23, 24).  Seven types of vancomycin-resistance associated 
genes have been described in Enterococci spp. These are vanA, B, C, D, E, G and L. 
Strains that harbor the vanA, B and D genes synthesize D-Ala-D-lactate, instead of D-
Ala-D-Ala, whereas vanC, E, G and L synthesize D-Ala-D-serine.  They are all 
responsible for creating reduced cell wall affinity to vancomycin and complete 
elimination or reduction in the cell wall terminating precursor D-Ala-D-Ala. VanA-type 
resistance is the most common and was first to be reported (23). It is characterized by a 
high level of resistance to vancomycin and teicoplanin that can also be induced (26). 
Vancomycin resistance has also been reported to be regulated by a two-component 
system VanSR (67). Changes in the peptidoglycan biosynthetic pathway results in high 
level of resistance to vancomycin and other glycopeptides in strains with the vanA 
phenotype in both Enterococcus faecium and E. faecalis (69).  In a medium containing 
glycopeptide, VanS, (Fig. 5) a membrane-associated sensor kinase which contains a 
histidine residue in its cytoplasmic domain, is phosphorylated. VanR, a transcriptional 
activator containing an aspartate catalyzes the transfer of the phosphoryl group from 
activated VanS. Thus, the level of phosphorylation of VanR is controlled by VanS. Co-
transcription of the vanH, vanA, vanX, and vanY genes is activated by the 
phosphorylated form of VanR by binding to the PRES promoter (74). Phosphorylated 
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VanR also activates transcription of the vanR and vanS genes by binding to the PREG 
promoter (73). 
 VanA and VanH synthesize D-Ala-D-lactate (69) and incorporate it into the 
peptidoglycan precursors to replace D-Ala-D-Ala (70, 71, 72). A dipeptidase VanX, 
hydrolyses D-Ala-D-Ala synthesized by the ligase thereby decreasing the production of 
the normal peptidoglycan precursor UDP-MurNAc-L-Ala-D-isoGlu-L-Lys-D-Ala-D-Ala 
(UDP-MurNAc-pentapeptide(Ala)) and  VanY, , a membrane-bound D, D-
carboxypeptidase enzyme removes the C-terminal  D-Ala residues of late peptidoglycan 
precursors (67, 73). All of these mechanisms increase resistance to vancomycin. 
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Figure 13: Mechanism of vancomycin resistance. Vancomycin prevents 
transglycosylation and cross-linking of the peptidoglycan during cell wall synthesis. 
Gene clusters that produces peptidoglycan D- Ala-D- Lactate instead of D-Ala-D-Ala 
have been found to be associated with VanA resistance. They include the vanH, vanA, 
vanX, vanS, vanR, and vanZ gene clusters (21). VanS is a sensor histidine kinase that 
senses the presence of vancomycin, VanR is the regulator that activates transcription of 
the operon. VanH is a dehydrogenase that produces lactate by converting pyruvate to 
D-lactic acid. VanX is a D, D-dipeptidase, which cleaves D-Ala-D-Ala, and VanA is a 
ligase that forms D-Ala-D-Lactate. VanY is a carboxypeptidase that cleaves the terminal 
D-ala (from pentapeptide to tetrapeptide). The role of VanZ is unknown (99). 
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Both in-vivo and in-vitro transfer of the vanA gene from Enterococci species to S. 
aureus results in a strain that is resistant to vancomycin. The first MRSA with a very 
high resistance to vancomycin (minimum inhibitory concentration >256 μg/ml) was 
isolated in 2002 (22).  
The past decade has recorded a remarkable increase in CDI treatment failure with both 
antibiotics (28). Therefore, a metronidazole-resistant strain was used to explore 
potential impact decreased susceptibility may have on the pathophysiology of recurrent 
CDI. High level of resistance was once not considered to be responsible (80), however, 
recent reports have demonstrated a causal relationship (30). 
A preliminary data (not shown) generated from our laboratory showed the present of C. 
difficile strains with significantly high-level resistant to metronidazole and vancomycin in 
the community. Presently, it is unclear how prevalent metronidazole and vancomycin 
resistant C. difficile strains are in healthcare communities. It is important to establish the 
prevalence of metronidazole and vancomycin resistance in C. difficile, determine the 
minimum inhibitory concentrations (MIC) of the different isolates and identify the 
mechanism of resistance in order to be able to design novel targeted therapies. 
Therefore, the purpose of this study was to determine the prevalence of metronidazole-
and-vancomycin resistance in Clostridium difficile strains isolated from patients and 
uncover the resistance mechanism.  
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MATERIALS AND METHODS 
Stool Samples  
        Clinical stool samples were obtained from inpatients, who presented with diarrhea 
at St. Luke’s Episcopal Hospital in the Texas Medical Center (TMC), Houston, Texas, 
and two hospitals in Kenya: Kenyatta National Hospital, Nairobi, and Kisii Teaching & 
Referral Hospital, Kissi. All the obtained clinical stool samples for this study was 
approved by the Institutional Review Boards of The University of Texas Health Science 
Center at Houston and St. Luke’s Episcopal Hospital (Houston, Texas),  and the ethical 
review boards of Kenyatta National Hospital and Kisii Teaching  and Referral Hospital. 
All the stool samples from patients were also de-identified. The samples from St. Luke’s 
were tested by their medical laboratory and reported as C. difficile positive, whereas the 
Kenyan samples were not tested for C. difficile by their respective microbiology 
laboratories. All samples were stored at -80oC until analyzed. 
C. difficile Detection 
The presence of C. difficile in the stools was determined using the C. difficile Plate 
Assay (CDPA). This method utilized an agar-based selective culture medium developed 
in our laboratory for differential analysis of C. difficile isolates (11). The assay 
differentiates toxin producing C. difficile from non–toxin producing colonies and 
concurrently inhibits growth of non- C. difficile colonies (11). CDPA is composed of brain 
heart infusion (BHI) medium (Becton Dickinson, Cockeysville, MD) (37 g), agar (14 g), 
defibrinated horse blood (7%) (Fisher Scientific, Pittsburgh, PA), 150 mg/ml 5-bromo-4-
chloro-3-indolyl-β-D-galactopyranoside (Zymo Research Irvine, CA), p-cresol (0.025%), 
D-cycloserine (300 mg) and cefoxitin (8.5 mg) (Fisher Scientific), per liter. 
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        A total of 572 stool samples were tested, of which 466 were obtained from St 
Luke’s Episcopal Hospital, 106 were from Kenyatta National Hospital, and Kisii 
Teaching and Referral Hospital. A loopful of each stool sample was spread on the 
CDPA plate and incubated anaerobically in an atmosphere of 10% H2, 5% CO2, and 
85% N2 in a Controlled Atmosphere Anaerobic Chamber (Plas Labs, Lansing, MI) for 48 
hours to facilitate both colony formation and toxin production. To enable the 
chromogenic reaction, which differentiates toxin from non-toxin producing C. difficile, the 
plates were exposed to oxygen at room temperature after the anaerobic incubation. 
Toxin producing colonies appeared blue while undetectable or non-toxin producing 
colonies appear pale white. 
Screening for Resistant Isolates 
CDPA plates containing 8 µg/ml of metronidazole (CDPA-Metro) and CDPA plates 
containing 4 µg/ml of vancomycin (CDPA-Van) were used in screening for 
metronidazole and vancomycin resistant isolates, respectively. The initial concentrations 
of vancomycin and metronidazole used were based on the CLSI break point (30). Using 
a sterilized loop, each C. difficile-positive stool sample was spread directly onto the 
CDPA-Metro and CDPA-Van plates and were incubated anaerobically at 37oC for 48 
hours. All stool samples were grouped into metronidazole-resistant only (Met-R only), 
these are stool samples that formed viable colonies on CDPA-Metro plates only,  
vancomycin-resistant only (Van -R only), these are stool samples that formed viable 
colonies on CDPA-Van plates only and both metronidazole and vancomycin resistant 
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(Met-Van-R) are stool samples that grew viable colonies on both CDPA-Metro and 
CDPA-Van plates (Fig. 6).  
 
 
Figure 14: Screening steps for isolating metronidazole- and vancomycin-resistant 
C. difficile colonies from stool samples. This chart details steps employed to screen 
the 466 stool samples from Texas and 102 stool samples from Kenya. CDPA plates 
were used to determine C. difficile positive stool samples, whereas CDPA + 
Metronidazole (8 μg/ml) and CDPA + Vancomycin (4 μg/ml) were used to screen for 
metronidazole- and vancomycin-resistant positive stool samples. 
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DNA Isolation 
Frozen isolates (stock of resistant isolates) were cultured in 5 ml BHI media 
supplemented with D-cycloserine (250 µg/ml) and cefoxitin (8.5 µg/ml), and were 
incubated anaerobically at 37oC overnight. DNA was isolated using Gen Elute Bacteria 
Genomic DNA Kit (Sigma-Aldrich, St. Louis, MO), following the manufacturer’s 
recommended procedure. The concentration of the isolated DNA was measured using a 
NanoDrop 2000 Spectrophotometer (Thermos Scientific, Waltham, MA). All DNA was 
stored at -20oC until analyzed. 
Toxin Analysis 
The C. difficile toxin activity (Cdifftox) assay was used to measure toxin activity in the 
resistant isolates. The Cdifftox assay employs the ability of the C. difficile toxins to 
cleave p-nitrophenyl-β-D-glucopyranoside into chromogenic nitrophenol, which can be 
measured spectrophotometrically at 410 nm (11). For the toxin test, 20 different 
resistant isolates with different MICs were cultured in BHI broth containing D-
cycloserine (250 µg/ml) and cefoxitin (8.5 µg/ml) and incubated at 37oC in anaerobic 
chamber (PLAS LABS, Lansing, MI) for 48 hours and the cells were harvested by 
centrifuging at 4000 rpm for 15 minutes.  The culture supernatants (250 µl) were added 
into a sterile Costar polystyrene 96-well plate and 30 µl of substrate (sterilized 30 mM of 
p-nitrophenyl-β-D-glucopyranoside in water) was added and incubated aerobically at 
37oC for 4- 24 hours. The cleaved substrate was measured at 410 nm wavelength using 
SPECTRAmax Plus 384 spectrophotometers (Molecular Devices, Sunnyvale, CA). 
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Determination of Minimum Inhibitory Concentrations 
The minimum inhibitory concentrations (MIC) of metronidazole and vancomycin were 
determined using two methods. These are the E-test Strip method (also called the 
(Epsilometer test) method (60), and the broth microdilution methods (60). 
(i) E-test Strip Method 
        E-test strip (Biomerieux inc, Durham, NC) is a gradient diffusion assay 
recommended by CLSI for determining antimicrobial susceptibility profile in both clinical 
and epidemiological surveillance (60). To assess the level of resistance, 53 resistant 
isolates from Texas were randomly selected (Table 1) and MICs for metronidazole and 
vancomycin were determined using the E-Strip method. The MIC range on the stripe 
was from 0.16 μg/ml to 256 μg/ml for both metronidazole and vancomycin. For the test, 
single colonies were picked from a CDPA plate and suspended in 1000 μl of sterile 1X 
phosphate buffered saline (PBS). A sterilized cotton swab was used to spread the 
culture onto a BHI agar plate containing 7% horse blood. Two different strips 
impregnated with gradient concentrations (0.16-256 µg/ml) of metronidazole or 
vancomycin were placed onto each plate using sterilized forceps and incubated 
anaerobically at 37o for 24 hours. The MICs were determined based on the zone of 
inhibition.  
 
 
 
 
27 
 
Table 1: Different number of Isolates and their corresponding resistance group.  
The minimum inhibitory concentration of metronidazole and vancomycin was 
determined on colonies selected from the metronidazole-resistant only (Met-R only), 
vancomycin-resistant only (Vanc-R only) and both metronidazole and vancomycin 
resistant (Met-Van-R) isolates. Overnight cultures of single colonies of each isolate 
were spread on BHI plates containing blood using a sterilized cotton swab. E-test strips 
containing graduated concentration of metronidazole and vancomycin (0.5 - 256µg/ml) 
were separately placed onto the plate and incubated anaerobically overnight at 37°C to 
determine their various MICs.  
 
Category Number of Isolates 
Met-R Only 15 
Van-R Only 4 
Met-Van-R 34 
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(ii) MIC Determination by the Broth Microdilution Method 
        Overnight cultures prepared from stored resistant colonies selected from CDPA 
plates were used. For the test, 4 µl of overnight cultures of each isolate was added in 
duplicate to a sterile Costar polystyrene 96-well plate (Corning Inc., NY) containing 200 
µl of BHI supplemented with D-cycloserine (250 µg/ml), cefoxitin (8.5 µg/ml), gradient 
concentrations of metronidazole or vancomycin (2-1024 µg/ml) separately and 
incubated anaerobically at 37oC for 24 hours. The optical densities of the culture were 
measured at a wavelength of 600 nm. 
PCR Amplification of the vanA gene in the isolates 
        PCR was used to examine the presence of the vanA gene in the vancomycin-
resistant C. difficile stored isolates. The amplification was performed using the primers: 
Forward 5’GGGAAAACGACAATTGC3’ and Reverse 5’GTACAATGCGGCCGTTA3’.  
The conditions used were: denaturation at 94oC for 2 min, 40 cycles of 94oC for 30 
secs, 55oC for 60 seconds, and 68oC for 90 seconds and a final elongation step at 68oC 
for 5 min. The PCR products were analyzed using 1% agarose gel electrophoresis and 
ethidium bromide staining.  
Ligation and Cloning 
Following amplification, the PCR products were purified with the Nucleic Acid 
Purification Kit (Epoch Life Science) following manufacturer directions. The DNA 
concentration was quantified using a Nanodrop 2000 Spectrophotometer. The purified 
PCR products were cloned into PCR II vector (Thermo Scientific) and sequenced at 
Lone Star Labs, Houston, Texas. For cloning and ligation, the manufacturer’s protocol 
was followed. Briefly, 10 μl of ligation reaction was set up using 50-200 ng DNA, 2 μl of 
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5X ExpressLink T4 DNA Ligase Buffer, 2 μl PCR II vector (25 ng/μl), 3μl of water, and 
1μl of ExpressLink T4 DNA Ligase. The ligation reaction was incubated at room 
temperature for 15 minutes and used for transformation as described below. 
Transformation 
Top10 competent cells were thawed on ice and 100 μl of the thawed competent cells 
was added into a microfuge tube on ice, 2 μl of each ligation reaction was added 
separately in each tube containing the competent cells. The content of each tube was 
gently mixed with a pipette, incubated on ice for 30 minutes, and 100 μl of the 
transformation reaction was spread on Luria Broth (LB) agar plates containing 100 
μg/ml of ampicillin and 150 μg/ml of X-gal. The plates were incubated at 37 oC 
overnight. The transformants (3 colonies each) were picked from each plate and 
cultured in LB broth containing 100 μg/ml ampicillin and incubated at 37o C in a MaxQ 
4000 shaker (Thermo Scientific) at 275 rpm overnight. Stocks were saved, and 
plasmids were isolated using Plasmid Isolation Kit (BioBasic Inc), as directed by the 
manufacturer. The concentration of each isolated plasmid was quantified using a 
Nanodrop 2000 Spectrophotometer and the plasmids were sent for sequencing at 
LoneStar Labs (Houston, Texas). 
Sequence Analysis 
The transformants containing the inserts with the plasmids were isolated and 
sequenced. The plasmid was identified and removed from the sequence. Both the 
forward and reverse sequences were merged using MAFFT and multiple sequence 
alignment was performed using CLUSTALW. 
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Biofilm Formation Analysis 
To evaluate the rate of adhesiveness or the amount of biofilm produced by the 
vancomycin-resistant isolates when exposed to vancomycin, three resistant isolates 62-
4, 255-1, and 67-2 were tested. The vancomycin MICs of these isolates determined by 
the broth microdilution method are (i) low resistance, MIC 4 µg/ml (isolate 62-4); (ii) 
intermediate resistance, MIC 64 µg/ml (isolate 255-1); and (iii) high resistance, MIC 
1024 µg/ml (67-2).  
Overnight cultures of the isolates were prepared in BHI supplemented with D-
cycloserine (250 µg/ml) and cefoxitin (8.5 µg/ml) and incubated anaerobically at 37oC. 
BHI medium supplemented with 1% glucose was prepared for the control, while BHI 
supplemented with 1% glucose and vancomycin at concentrations corresponding to ½ 
and ¼ of the MICs of the isolates was prepared for the experimental as follows:   
(1) Low resistance, MIC 4 µg/ml (62-4): BHI supplemented with 1% glucose 
containing 2 µg/ml or 1 µg/ml vancomycin. 
(2)  Intermediate resistance, MIC 64 µg/ml (isolate 255-1): BHI supplemented with 
1% glucose containing 32 µg/ml or 16 µg/ml of vancomycin. 
(3)  High resistance, MIC 1024 µg/ml (67-2): BHI supplemented with 1% glucose 
containing 512 µg/ml or 256 µg/ml vancomycin. 
 For the control without vancomycin, 200 µl of overnight culture of each of the isolates 
were added in triplicate into 24-well polystyrene plates containing 1800 µl of BHI 
supplemented with 1% glucose.  For the experimental group, 200 µl of the culture were 
added in triplicate into 24-well polystyrene plates and 1800 µl of BHI supplemented with 
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1% glucose containing different concentrations of vancomycin, as described above.  All 
the samples were incubated at 370C anaerobically for 72 hours.  
Following the incubation period, the amount of biofilm produced was measured (59). 
Briefly, the supernatant of all the wells was gently removed and each well was washed 
twice with 2000 µl of sterilized 1X PBS. The plates were dried at 60oC for 1 hour. The 
dried wells were stained with 150 µl of 2% crystal violet and incubated at 37oC for 15 
minutes. The excess stain was washed out with deionized water and the plates were 
dried at 60oC for 10 minutes. The crystal violet bound to the adherent cells was 
extracted with 1800 µl of 100% ethanol. The optical density was measured at 570 nm 
wavelength using SPECTRAmax Plus 384 spectrophotometers. The experiment and 
the assay were performed three times. 
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RESULTS 
To determine the prevalence of metronidazole-and-vancomycin resistance in C. difficile, 
all the C. difficile positive stool samples and stool samples containing metronidazole- 
resistant and vancomycin-resistant C. difficile were enumerated and classified as 
follows. Stool samples that contains C. difficile that grew on CDPA plates were 
classified as C. difficile positive stool samples whereas, those that did not grow were 
classified as C. difficile negative stool samples. All stool samples that contain C. difficile 
strains that grew on plates containing metronidazole only were grouped as 
metronidazole only resistant stool sample (Met-R), all stool samples that contain C. 
difficile strains that grew on plates containing vancomycin only were grouped as 
vancomycin only resistant stool sample (Van-R) and all stool samples that contain C. 
difficile strains that grew on both metronidazole and vancomycin plates were grouped 
as metronidazole-vancomycin resistant stool sample (Met-Van-R). 
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Table 2: Distribution of the number of patients having metronidazole- and 
vancomycin-resistant C. difficile strains in their stool. The samples were 
grouped as described, Met-R, Van-R and Met-Van-R. The total number and percent 
relative to the C. difficile positive samples, metronidazole- and vancomycin- resistant from 
both Texas and Kenya patients is shown. 
 
 
Texas  
N (%) 
Kenya 
N (%) 
C. difficile positive stools         438 (93.9) 98 (96) 
   
Met-R Only    31 (7) 26 (26.5) 
Vanc-R Only 17 (3.9) 9 (9.1) 
Met-Van-R 97 (22.1) 57 (58.2) 
Total Met-R 128 (29.2) 83 (84.7) 
Total Van-R 114 (26) 66 (67.3) 
Total (Met-R + Van-R 145 (33.1) 92 (93.9) 
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  Distribution of Metronidazole- and Vancomycin-Resistant C. difficile in CDI 
Patients 
        To determine the percent of C. difficile positive stool samples, metronidazole and 
vancomycin resistant stool in samples from Texas and Kenya, the number of C. difficile 
positive and negative stool samples were enumerated and grouped (Table 2) as 
metronidazole resistant stool samples (Met-R only), vancomycin-resistant only (Van-R 
only) samples, and both metronidazole and vancomycin resistant stool samples (Met-
Van-R).  
        To establish the prevalence of metronidazole- and vancomycin-resistant C. difficile, 
CDI-positive stool samples were plated on CDPA plates containing either metronidazole 
or vancomycin at their reported CLSI cutoff values (8 µg/ml and 4 µg/ml respectively). 
All stool samples that grew viable colonies only on the metronidazole-containing plates 
were grouped as (Met-R only), stools that grew viable colonies only on the vancomycin-
containing plates (Van-R only) and stools samples that grew colonies on both 
metronidazole and vancomycin plates (Met-Van-R). From Texas stool samples 438 
(93.9%) contained colonies that were C. difficile positive, 31 (7%) were Met-S only, 17 
(3.9%) were Vanc-R only and 97 (22.1%) were Met-Van-R. From the Kenya stool 
samples, 98 (96%) were C. difficile positive, 26 (26.5%) were Met-R only, 9 (9.1%) were 
Vanc-R only and 57 (58.2%) were Met-Van-R. (Table 2). Overall, the total numbers of 
resistant stool samples were Met-R, 128 (29.2%), Van-R, 114 (26%) and Met-Van-R 
145 (33.1%).  
For further analysis, five different colonies were selected from each plate containing 
resistant stool samples from Texas and at least two from the Kenyan stools. All the 
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colonies were picked and cultured anaerobically overnight in BHI broth containing D-
cycloserine (250 µg/ml), cefoxitin (8.5 µg/ml) and their respective antibiotics (8 μg/ml of 
metronidazole or 4 μg/ml of vancomycin). The number of viable colonies that represent 
the number of stored independent isolates from all the metronidazole and vancomycin 
resistant stool samples was recorded (Fig. 7).  
 
 
Figure 15: Isolation of metronidazole- and vancomycin-resistant C. difficile 
colonies from the stools. CDI stools were plated on CDPA plates containing either 
metronidazole (8µg/ml) or vancomycin (4 µg/ml). Following a 24-hour incubation, 
colonies (5 from Texas and at least 2 from Kenya stools) were selected for further 
analysis.  
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Characteristics of the Colonies Based on Morphology and Toxin Production 
Of the C. difficile positive stool samples from Texas and Kenya, 157 (35.9%) and 5 
(5.1%), respectively, of the samples produced only blue colonies on the CDPA plates, 
indicative of active toxin production. On the other hand, the plates for 122 (27.9%) of the 
Texas samples and 9 (9.2%) of the Kenya samples produced had only white colonies 
(Table 3). This suggests that the colonies were not producing active toxins or cannot 
produce active toxins. The colonies from 159 (36.3%) of Texas and 84 (85.7%) of the 
Kenyan patients had mixed blue and white (both toxin and non-toxin) colonies on the 
plates. 
The sizes of the colonies in each plate were also analyzed and classified as (a) small, 
(b) medium, (c) large, and (d) a mixture. The classification is the different sizes 
observed and therefore, subjective. Of the stool samples analyzed, 245 of the patients 
from Texas and 45 patients from Kenya had C. difficile isolates that formed only small 
colonies. Further, 49 of the Texas and 3 of the Kenyan samples formed medium sized 
colonies only, whereas 18 of the Texas and 6 of the Kenyan samples formed large 
colonies only. Also, 58 of the Texas and 20 of the Kenyan samples formed a mixture of 
small and medium colonies, while 10 (Texas) and 1 (Kenya) samples formed a mixture 
of medium and large colonies. Finally, 42 of the Texas and 19 of the Kenyan samples 
formed a mixture of small and large colonies whereas 16 (Texas) and 4 (Kenyan) 
samples formed a mixture of small, medium and large colonies. These results indicated 
that many Texas and most Kenyan CDI patients are infected with C. difficile strains that 
are morphologically different. 
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Table 3: The characteristics of the C. difficile colonies isolated from patients from 
Texas and Kenya.  
 
Morphology Texas 
Number of 
Samples 
Kenya 
Number of 
Samples 
Small colonies only 245 45 
Medium colonies only 49 3 
Large colonies only 18 6 
Mixture of small and 
medium colonies 
58 20 
Mixture of medium and 
large colonies 
10 1 
Mixture of large and 
small colonies 
42 19 
Mixture of small, medium 
and large  
16 4 
Total 438 98 
Blue colonies only 157 5 
While colonies only 122 9 
Mixture of white and blue 
colonies 
159 84 
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The Minimum Inhibitory concentrations (MIC) of the C. difficile strains  
To determine the MICs of the isolates from metronidazole- and vancomycin-resistant 
stools, the E-test strip assay was used to test 53 randomly selected isolates from 
Texas. The result revealed that the metronidazole MIC of 52 (98.1%) of the isolates was 
greater than 256 µg/ml, and only 1 (1.9%) was sensitive with an MIC 1.0 µg/ml (Table 
4). Also, the vancomycin MIC of 35 of the isolates (77.4%) was greater than 256 µg/ml, 
5 had MICs between 8-16 µg/ml, whereas 12 (22.6%) had MICs less than 4 µg/ml. 
Since the majority of the 53 samples initially tested by the E-test strip method have 
MICs greater than 256 µg/ml, the broth microdilution method was used to determine the 
exact MICs of all the resistant isolates. This is because this method does not have a 
limitation on the antibiotic concentration to be tested, contrary to the E-test strip method 
whose maximum concentration is 256 µg/ml for both metronidazole and vancomycin.   
 
Out of 145 resistant isolates from Texas, three isolates did not grow in the liquid, so 142 
were tested for their MIC using broth microdilution method. From this analysis, 80% 
(114 out of 142 resistant isolates) from Texas colonies were vancomycin resistant with 
MIC >16 µg/ml whereas 41% (38 out of 92 resistant isolates) from Kenya were 
vancomycin resistant with MIC >16 µg/ml. 97.8% (139 out of 142 resistant isolates) from 
Texas population were metronidazole resistant with MICs ˃ 256 µg/ml whereas 97% (90 
out of 92 resistant isolates) from Kenya were metronidazole resistant with MICs > 256 
µg/ml. 
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Table 4: The MIC of 53 C. difficile isolates using E-test strip method. The MIC 
breakpoint was based on guideline recommended for anaerobes by Clinical and 
Laboratory Standard Institute (CLSI), which is 8 µg/ml for metronidazole and 4 µg/ml for 
vancomycin.  
 
Number of Isolates 
Concentration 
(μg/ml) 
Metronidazole Vancomycin 
0.5 - 1 
1 1 - 
2 - 8 
3 - 3 
4 - - 
8 - 2 
12 - 2 
16 - 2 
>256 52 35 
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Pearson’s test of association between resistance and location showed a high tendency 
of C. difficile isolates to be metronidazole resistant in Kenya than Texas (p-value ≤ 
0.001). This might be as a result of frequent self-medication with metronidazole. 
Unexpectedly, the tendency to develop vancomycin resistant is equally higher in Kenya 
than Texas (p-value ≤ 0.001), even with no history of vancomycin treatment. Both 
metronidazole- and- vancomycin resistance were prevalent in Kenya than Texas. 
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Table 5: The MICs of the metronidazole and vancomycin-resistance C. 
difficile isolates determined using the broth microdilution method.  
 
Metronidazole Vancomycin 
Concentration 
(µg/ml) 
Texas 
(n= 142) 
Kenya  
(n= 92) 
Texas 
(n= 142) 
Kenya 
(n= 92) 
 2 3 2 11 42 
4 - - 10 3 
8 - - 4 2 
16 - 1 3 7 
32 - - 1 5 
64 4 1 4 2 
128 3 - 1 5 
256 2 4 9 7 
512 7 8 23 4 
>1024 123 76 76 15 
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Table 6: Distribution of the isolates based on both CLSI and European Committee 
on Antimicrobial Susceptibility Testing (EUCAST) guidelines. CLSI and EUCAST 
Cut off values are as follows: EUCAST: Susceptible is ≤2mg/L, Resistant is ˃2mg/L and 
the Cut off is ≤2mg/L, for both metronidazole and vancomycin. CLSI: ≤8/16/ ≥32 
(Sensitive/Intermediate/Resistant) for metronidazole and ≥4µg/ml for vancomycin. 
 
Texas (n = 142) 
 
   Kenya (n = 92) 
 
 
CLSI EUCAST CLSI EUCAST 
Metronidazole 
resistant only 
11 11 42 42 
Vancomycin 
resistant only 
3 3 2 2 
Both 
Metronidazole 
and 
Vancomycin 
resistant 
128 128 48 48 
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Cluster Analysis of the MICs 
        Cluster analysis reveals that a significant number of the isolates (123/145 for the 
Texas isolates and 76/91 for the Kenya isolates) had MIC >1024 µg/ml for 
metronidazole.  There was a wide gap in MIC range among the metronidazole isolates 
in both patient populations with 139 (97.9%) having MIC >64 µg/ml (for the Texas 
samples) and 89 (96.7%) for Kenyan samples (Fig. 8). The MICs for the vancomycin-
resistant isolates were spread across different concentrations in both patient 
populations. However, a higher number of the isolates 99 (68.3%) had vancomycin MIC 
of ≥512 µg/ml for the Texas samples. Remarkably, isolates with resistance to high 
levels of metronidazole was predominant in both Texas and Kenyan patients. Based on 
the distribution of the MICs, the resistant isolates can be grouped into three categories: 
(i) Low resistance (4-16 µg/ml); (ii) intermediate resistance (32-64 µg/ml); and (iii) high 
resistance (64 - ˃1024 µg/ml). 
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Figure 16: Distribution of metronidazole- and vancomycin-resistant Texas and 
Kenyan C. difficile isolates based on MICs. The red line is the median and the solid 
line represents number of highly resistant isolate with MIC of 1024 µg/ml. Each dot 
represents a colony. 
CLSI cutoff= 4 µg/mL 
Vancomycin 
  CLSI cutoff= 8 µg/mL 
Metronidazole 
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  Analysis of Toxin Production in Both Texas and Kenya Resistant Isolates 
Twenty isolates with different levels of resistance (Fig. 9) from Texas and Kenya were 
selected to explore the association between toxin production and antibiotic resistance. 
The isolates were grown in BHI containing D-cycloserine (250 µg/ml) and cefoxitin (8.5 
µg/ml) anaerobically at 37oC for 48 hours. The culture supernatants were tested for 
toxin activity by mixing 250 µl of the supernatant with 30 µl of the substrate. Sixteen out 
of twenty isolates from Texas were toxin positive (Tox+) whereas 15 out of the twenty 20 
isolates from Kenya were Tox+. 
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Figure 17. Analysis of toxin production by the metronidazole and vancomycin 
resistant isolates. Both toxin-producing (Tox+) and non-toxin-producing (Tox-) isolates 
are represented from different groups of resistant isolates: low resistance (4-16 μg/ml), 
intermediate resistance (32-64 μg/ml) and high resistance (32-64 μg/ml). Stored isolates 
(20) were cultured for 48 hours and 250 µl of each culture supernatant was incubated 
with toxin substrate (30 mM p-nitrophenyl-β-D-glucopyranoside) for 4 hours. The toxin 
present in culture supernatant cleaves the chromogenic toxin substrate and generates 
yellow colored nitrophenol whose absorbance is read at 410nm in a spectrophotometer.  
 
 
 
47 
 
Analysis of Biofilm Formation of the Resistant Isolates 
Biofilm has been suggested to be associated with vancomycin resistance (30). To 
investigate the effect of vancomycin on the ability of the resistant isolates to form 
biofilms, isolates with different MICs were evaluated. This experiment was based on the 
hypothesis that if the low- and intermediate-resistant isolates, but not highly-resistant 
isolates, use biofilm as a defensive mechanism when exposed to vancomycin, then the 
degree of biofilm formation in those isolates should increase. To test this hypothesis, 
the isolates were exposed to sub-inhibitory concentrations of vancomycin for 72 hours 
and biofilm production was measured.  There was no significant difference (p=0.3554) 
in the amount of biofilm produced in the presence or absence of vancomycin in all the 
isolates tested (Fig. 10). 
 
 
 
 
 
 
 
 
 
 
48 
 
 
 
Figure 10: Effect of vancomycin on biofilm formation on vancomycin-resistant C. 
difficile isolates. Cultures with different vancomycin MICs were exposed to different 
amounts of vancomycin for 72 hours and biofilm produced was measured. The blue, 
purple, and green bars represent the low, intermediate and high resistant isolates 
respectively. The different isolates were grown without vancomycin, or in the presence 
of vancomycin at concentrations equivalent to ¼ MIC or ½ MIC values of the isolates. 
Error bars represent the standard deviation from three independent replicates. 
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 PCR- Based Detection of the vanA Gene in the Vancomycin Resistant Isolates. 
        To evaluate the presence of vanA gene in the resistant isolates, PCR was 
performed using a primer pair specific for vanA in Enterococcus faecium.  A total of 40 
vancomycin resistant isolates were tested and all were positive for the vanA gene (Fig. 
11).  
 
 
 
Figure 11: A representative agarose gel electrophoresis images showing the 
expected vanA bands in the C. difficile isolates tested. Genomic DNA was isolated 
from the resistant isolates and used as templates for PCR with primers specific for the 
vanA gene in E. faecium. The PCR product was resolved on 1% agarose and stained 
with ethidium bromide. M is 1kb DNA marker, lanes 1 and 14 are the vanA amplicons 
and –VE is the negative control with no DNA. 
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Sequence Comparison of Putative C. difficile vanA gene with the Enterococcus 
Faecium Homolog 
        To confirm the presence of the C. difficile vanA gene and also enable comparison 
to the E. faecium homolog, the vanA PCR products were purified and sequenced. The 
sequence alignment is shown (Fig. 12). When C. difficile vanA sequence is compared to 
vanA of E. faecium there is a significant measure of divergence in the 5’ end compared 
to 3’ end which is more conserved.  
 
 
 Figure 12: Sequence alignment from the PCR product of the amplified segment 
of the C. difficile vanA gene. The alignment appears to be divergent at the 5’ region 
and more conserved in the 3’.  
 
 
 
                               90       100       110       120       130       140       150       160         
                      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
Enterococcus faecium  AAAA-TCTGCAATAGAGATAGCCGCTAACATTAATAAAGAAAAATACGAGCCGTTATACATTGGAATTACGAAATCTGGT  
394-3L-VANA           --------------------------------------------------------------------------------  
382-3BA-VANA          AAAAATCTGCAATAGAGATAGCCGCTAACATTAATAAAGAAAAATACGAGCCGTTATACATTGGAATTACGAAATCTGGT  
382-3AA-VANA          --------------------------------------------------------------------------------  
244-4A-VANA           --------------------------------------------------------------------------------  
237-2-VANA            --------------------------------------------------------------------------------  
231-4A-VANA           AAAA-TCTGCAATAGAGATAGCCGCTAACATTAATAAAGAAAAATACGAGCCGTTATACATTGGAATTACGAAATCTGGT  
212-5A-VANA           --------------------------------------------------------------------------------  
134-2L-VANA           --------------------------------------------------------------------------------  
382-3AA1-VANA1        AAA--TCTGCAATAGAGATAGCCGCTAACATTAATAAAGAAAAATACGAGCCGTTATACATTGGAATTACGAAATCTGGT  
244-4A1-VANA1         AAAA-TCTGCAATAGAGATAGCCGCTAACATTAATAAAGAAAAATACGAGCCGTTATACATTGGAATTACGAAATCTGGT  
212-5A1-VANA1         AAAA-TCTGCAATAGAGATAGCCGCTAACATTAATAAAGAAAAATACGAGCCGTTATACATTGGAATTACGAAATCTGGT  
 
                              170       180       190       200       210       220       230       240        
                      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
Enterococcus faecium  GTATGGAAAA-TGTGCGAAAAACCTTGCGCGGAATGGGAAAACGACA-ATTGCTATTCAGC-TGTACTCTCGCC-GGATA  
394-3L-VANA           ---------------------------------------------------------------GCACGTCGGTC------  
382-3BA-VANA          GTATGGAAAAATGTGCGAAAAACCTTGCGCGGAATGGGAAAACGACA-ATTGCTATTCAGC-TGTACTCTCGCC-GGATA  
382-3AA-VANA          ------------------------------TTGGGGAAAAAACGG---ATTGCTATTCATTGTGTACTCTCGCC-GGATA  
244-4A-VANA           -------------------------------GATTGGGAAAAAAAGGAATTGCTTTTCAGC-TGTACTCTCGCC-GGATA  
237-2-VANA            ---------------------------------------------------------------GCAAGTCGGTG------  
231-4A-VANA           GTATGGAAAA-TGTGCGAAAAACCTTGCGCGGAATGGGAAAACGACA-ATTGCTATTCAGC-TGTACTCTCGCC-GGATA  
212-5A-VANA           ---------------------------------TGGGAAAAAAAACGCATTGCTATTCAGC-TGTACTCTCGCC-GGATA  
134-2L-VANA           ---------------------CCCTTCCCTTTGGGGGTAAAACGACAAATTGTTATTCAGC-TGTACTCTCCCCCGGATA  
382-3AA1-VANA1        GTATGGAAAA-TGTGCGAAAAACCTTGCGCGGAATGGGAAAACGAC-AATTGCTATTCAGC-TGTACTCTCGCC-GGATA  
244-4A1-VANA1         GTATGGAAAA-TGTGCGAAAAACCTTGCGCGGAATGGGAAAACGAC-AATTGCTATTCAGC-TGTACTCTCGCC-GGATA  
212-5A1-VANA1         GTATGGAAAA-TGTGCGAAAAACCTTGCGCGGAATGGGAAAACGAC-AATTGCTATTCAGC-TGTACTCTCGCC-GGATA  
 
                              250       260       270       280       290       300       310       320        
                      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
Enterococcus faecium  AAAAAATGCACGG-ATTACTTGTTAAAAAGAACCATGAATATGAAATCAACCATGTTGATGTAGCATTTTCAGCTTTGCA  
394-3L-VANA           -----GTGCACGG-ATTACTTGTTAAAAAGAACCATGAATATGAAATCAACCATGTTGATGTAGCATTTTCAGCTTTGTA  
382-3BA-VANA          AAAAAATGCACGG-AT-ACTTGTTAAAA-GAACCATGAATATGAAATCAACCATGTTGATGTAGCATTTTCAGCTTTGCA  
382-3AA-VANA          AAAAAATGCACGG-AT-ACTTGTTAAAA-GAACCATGAATATGAAATCAACCATGTTGATGTAGCATTTTCAGCTTTGCA  
244-4A-VANA           AAAAAATGCACGG-AT-ACTTGTTAAAA-GAACCATGAATATGAAATCAACCATGTTGATGTAGCATTTTCAGCTTTGCA  
237-2-VANA            ----GATGCACGGCATTACTTGTTAGAA-GAACCATGA-TATCGACTCAACCATGTTGATGTAGCATTTTCAGCTTTG-A  
231-4A-VANA           AAAAAATGCACGG-AT-ACTTGTTAAAA-GAACCATGAATATGAAATCAACCATGTTGATGTAGCATTTTCAGCTTTGCA  
212-5A-VANA           AAAAAATGCACGG-AT-ACTTGTTAAAA-GAACCATGAATATGAAATCAACCATGTTGATGTAGCATTTTCAGCTTTGCA  
134-2L-VANA           AAAAAATGCACGG-AT-ACTTGTTAAAA-GA-CCATGAATATGAAATCAACCATGTTGATGTAGCATTTTCAGCTTTGCA  
382-3AA1-VANA1        AAAAAATGCACGG-ATTACTTGTTAAAAAGAACCATGAATATGAAATCAACCATGTTGATGTAGCATTTTCAGCTTTGCA  
244-4A1-VANA1         AAAAAATGCACGG-ATTACTTGTTAAAAAGAACCATGAATATGAAATCAACCATGTTGATGTAGCATTTTCAGCTTTGCA  
212-5A1-VANA1         AAAAAATGCACGG-ATTACTTGTTAAAAAGAACCATGAATATGAAATCAACCATGTTGATGTAGCATTTTCAGCTTTGCA  
51 
 
VanA Amino Acid Sequence Alignment  
The DNA sequences obtained from the isolates were translated into amino acid and 
aligned to the vanA amino acid sequence from Enterococcus faecalis (Fig. 13). Cluster 
analysis was performed to determine the percentage of similarity and most of the 
sequences were 97.27-100% similar. It appears the differences in the sequence did not 
impact the antibiotic resistance activity as the isolate with the lowest similarity in the 
sequence has a high degree of vancomycin resistance of 512 μg/ml compared to as the 
others. However, due to the low quality of the sequences obtained at the 5’ and 3’ ends, 
we were not able to obtain the full-length version of the C. difficile vanA from the 
isolates. This will be addressed in a planned future study. 
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Figure 13: VanA amino acid sequence alignment of the resistant isolates. 
                          10        20        30        40        50        60        70        80                
                 ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
E-faecalis_VanA  PVGGCSEEHDVSVKSAIEIAANINKEKYEPLYIGITKSGVWKMCEKPCAEWENDNCYSAVLSPDKKMHGLLVKKNHEYEI  
382-3A           --------------------------------------------------XENDNCYSAVLSPDKKMHGLLVKKNHEYEI  
KSI-031A         --------------------------------------------------XENDNCYSAVLSPDKKMHGLLVKKNHEYEI  
KNH-009          --------------------------------------------------XENDNC*SAVLSPDKKMHGLLVKKNHEYEI  
KNH-006C         --------------------------------------------------XENDNCYSAVLSPDKKMHGLLVKNNHEYEI  
302-3            --------------------------------------------------XENDNCYSAVLSPDKKMHGLLVKKNHEYEI  
KNH-007          --------------------------------------------------XENDNCYSAVLSPDKKMHGLLVKKNHEYEI  
231-A            --------------------------------------------------XENDNCYSAVLSPDKKMHGLLVKKNHEYEI  
KNH-011          --------------------------------------------------XENDNCYSAVLSPDKKMHGLLVKKNHEYEI  
157-4            --------------------------------------------------XENDNCYSAVLSPDKKMHGLLVKKNHEYEI  
233-2            --------------------------------------------------XENDNCYSAVLSPDKKMHGLLVKKNHEYEI  
KSI090           --------------------------------------------------XENDNCYSAVLSPDKKMHGLLVKKNHEYEI  
212-5            --------------------------------------------------XENDNCYSAVLSPDKKMHGLLVKKNHEYEI  
KSI-064          --------------------------------------------------XENDNCYSAVLSPDKKMHGLLVKKNHEYEI  
134-2            --------------------------------------------------XENDNCYSAVLSPDKKMHGLLVKKNHEYEI  
 
                          90       100       110       120       130       140       150       160         
                 ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
E-faecalis_VanA  NHVDVAFSALHGKSGEDGSIQGLFELSGIPFVGCDIQSSAICMDKSLTYIVAKNAGIATPAFWVINKDDRPVAATFTYPV  
382-3A           NHVDVAFSALHGKSGEDGSIQGLFELSGIPFVGCDIQSSAICMDKSLTYIVAKNAGIATPAFWVINKDDRPVAATFTYPV  
KSI-031A         NHVDVAFSALHGKSGEDGSIQGLFELSGIPFVGCDIQSSAICMDKSLTYIVAKNAGIATPAFWVINKDDRPVAATFTYPV  
KNH-009          NHVDVAFSALHGKSGEDGSIQGLFELSGIPFVGCDIQSSAICMDKSLTYIVAKNAGIATPAFWVINKDDRPVAATFTYPV  
KNH-006C         NHVDVAFSALHGKSGEDGSIQGLFELSGIPFVGCDIHSSAICMDKSLTYIVAKNAGIATPAFWVINKDDRPVAATFTYPV  
302-3            NHVDVAFSALHGKSGEDGSIQGLFELSGIPFVGCDIQSSAICMDKSLTYIVAKNAGIATPAFWVINKDDRPVAATFTYPV  
KNH-007          NHVDVAFSALHGKSGEDGSIQGLFELSGIPFVGCDIQSSAICMDKSLTYIVAKNAGIATPAFWVINKDDRPVAATFTYPV  
231-A            NHVDVAFSALHGKSGEDGSIQGLFELSGIPFVGCDIQSSAICMDKSLTYIVAKNAGIATPAFWVINKDDRPVAATFTYPV  
KNH-011          NHVDVAFSALHGKSGEDGSIQGLFELSGIPFVGCDIQSSAICMDKSLTYIVAKNAGIATPAFWVINKDDRPVAATFTYPA  
157-4            NHVDVAFSALHGKSGEDGSIQGLFELSGIPFVGCDIQSSAICMDKSLTYIVAKNAGIATPAFWVINKDDRPVAATFTYPV  
233-2            NHVDVAFSALHGKSGEDGSIQGLFELSGIPFVGCDIQSSAICMDKSLTYIVAKNAGIATPAFWVINKDDRPVAATFTYPV  
KSI090           NHVDVAFSALHGKSGEDGSIQGLFELSGIPFVGCDIQSSAICMDKSLTYIVAKNAGIATPAFWVINKDDRPVAATLTYPV  
212-5            NHVDVAFSALHGKSGEDGSIQGLFELSGIPFVGCDIQSSAICMDKSLTYIVAKNAGIATPAFWVINKDDRPVAATFTYPV  
KSI-064          NHVDVAFSALHGKSGEDGSIQGLFELSGIPFVGCDIQSSAICMDKSLTYIVAKNAGIATPAFWVINKDDRPVAATFTYPV  
134-2            NHVDVAFSALHGKSGEDGSMQGLFELSGIPFVGCDIQSSAICMDKSLTYIVAKNAGITTPAFGVINKEDRPGAVTLTYPV  
 
                         170       180       190       200       210       220       230       240        
                 ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
E-faecalis_VanA  FVKPARSGSSFGVKKVNSADELDYAIESARQYDSKILIEXAVSGCEVGCAVLGNSAALAVGEVDQIRLQYGIFRIHQEVE  
382-3A           FVKPARSGSSFGVKKVNSADELDYAIESARQYDSKILIEQAVSGCEVGCAVLGNSAALAVGEVDQIRLQYGIFRIHQEVE  
KSI-031A         FVKPARSGSSSGVKKVNSADELDYAIESARQYDSKILIEQAVSGCEVGCAVLGNSAALAVGEVDQIRLQYGIFRIHQEVE  
KNH-009          FVKPARSGSSFGVKKVNSADELDYAIESARQYDSKILIEQAVSGCEVGCAILGNSAALAVGEVDQIRLQYGIFRIHQEVE  
KNH-006C         FVKPARSGSSFGVKKVNSADELDYAIESARQYDSKILIEQAVSGCEVGCAVLGNSAALAVGDVDQIMLQYGIFRIHQEVE  
302-3            FVKPARSGSSFGVKKVNSADELDYAIESARQYDSKILIEQAVSGCEVGCAVLGNSAALAVGEVDQIRLQYGIFRIHQEVE  
KNH-007          FVKPARTGSSFGVKKVNSADELDYAIESARQYDSKILIEQAVSGCEVGCAVLGNSAALAVGEVDQIRLQYGIFRIHQEVE  
231-A            FVKPARSGSSFGVKKVNSADELDYAIESARQYDSKILIEQAVSGCEVGCAVLGNSAALAVGEVDQIRLQYGIFRIHQEVE  
KNH-011          FVKPARSGSSFGVKKVNSADELDYAIESARQYDSKILIEQAVSGCEVGCAVLGNSAALAVGEVDQIRLQYGIFRIHQEVE  
157-4            FVKPARSGSSFGVKKVNSADELDYAIESARQYDSKILIEQAVSGCEVGCAVLGNSAALAVGEVDQIRLQYGIFRIHQEVE  
233-2            FVKPARSGSSFGVKKVDSADELDYAIESARQYDSKILIEQAVSGCEVGCAVLGNSAALAVGEVDQIRLQYGIFRIHQEVE  
KSI090           FVKPARSGSSFGVKKVNSADELDYAIESARQYDSKILIEQAVSGCEVGCAVLGNSAALAVGEVDQIRLQYGIFRIHQEVE  
212-5            FVKPARSGSSFGVKKVNSADELDYAIESARQYDSKILIEQAVSGCEVGCAVLGNSAALAVGEVDQIRLQYGIFRIHQEVE  
KSI-064          FVKPARSGSSFGVKKVNSADELDYAIESARQYDSKILIEQAVSGCEVGCAVLGNSAALAVGEVDQIRLQYGIFRIHQEVE  
134-2            LVNPERSGSSFGVKKVNTADK*NYAIESARQYDSKILID*VVSGCEVGGAVLGNRAALAVGEVDQIRLQYGIFRINQEVE  
 
                         250       260       270       280       290       300       310       320        
                 ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
E-faecalis_VanA  PEKGSENAVITVPADLSAEERGRIQETAKKIYKALGCRGLARVDMFLQDNGRIVLNEVNTLPGFTSYSRYPRMMAAAGIA  
382-3A           PEKGSENAVITVPADLSAEERGRIQETAKKIYKALGCRGLARVDMFLQDNGRIVX-------------------------  
KSI-031A         PEKGSENAVITVPADLSAEERGRIQETAKKIYKALGCRGLARVDMFLQDNGRIVX-------------------------  
KNH-009          PEKGSENAVITVPADLSAEERGRIQETA*KIYKALGCTGLARVDMFLQDNGRIVX-------------------------  
KNH-006C         PEKGSENANITGPADLSAEERGRIPETAK*IYKALGCTCLARVDMILQDNGRIVX-------------------------  
302-3            PEKGSENAVITVPADLSAEERGRIQETAKKIYKALGCRGLARVDMFLQDNGRIVX-------------------------  
KNH-007          PEKGSENAVITVPADLSAEERGRIQETAKKIYKALGCRGLARVDMFLQDNGRIVX-------------------------  
231-A            PEKGSENAVITVPADLSAEERGRIQETAKKIYKALGCRGLARVDMFLQDNGRIVX-------------------------  
KNH-011          PEKGSENAVITVPGDLSAEERGRIQETAKKIYKALGCRGLARVDMFLQDNGRIVX-------------------------  
157-4            PEKGSENAVITVPADLSAEERGRIQETAKKIYKALGCRGLARVDMFLQDNGRIVX-------------------------  
233-2            PEKGSENAVITVPADLSAEERGRIQETAKKIYKALGCRGLARVDMFLQDNGRIVX-------------------------  
KSI090           PEKGSENAVITVPADLSAEERGRIQETAKKIYKALGCRGLARVDMFLQDNGRIVX-------------------------  
212-5            PEKGSENAVITVPADLSAEERGRIQETAKKIYKALGCRGLARVDMFLQDNGRIVX-------------------------  
KSI-064          PEKGSENAVITVPADLSAEERGRIQETAKKIYKAHGCRGLARVDMFLQDNGRIVX-------------------------  
134-2            PEKGSENAVIPVPADLSAEERGRIQETAKKIYKALAXRXLARVIMXLXDYGRMVX-------------------------  
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DISCUSSION 
Clostridium difficile infections are the most common hospital acquired infection and 
currently treated with metronidazole and vancomycin (4). The unexpectedly high 
percent of C. difficile metronidazole and vancomycin resistant isolates from a 
preliminary study in our laboratory was of great concern and led to the hypothesis that 
metronidazole and vancomycin resistant C. difficile is more widespread in the patient 
population that previously envisaged. The objective of this study was to determine the 
prevalence of metronidazole- and- vancomycin resistance in C. difficile strains and 
uncover the resistance mechanism. 
The result of the initial analysis of the metronidazole and vancomycin resistant C. 
difficile strains in stools of diarrhea patients from Texas and Kenya demonstrated that 
metronidazole and vancomycin resistance is prevalent in CDI patients. Our analysis to 
determine the level of metronidazole and vancomycin resistance of each isolate from 
the stool sample revealed a high degree of resistance to either or both antibiotics. The 
two methods of MIC determination (E-test strip and broth microdilution assays) showed 
C. difficile isolates with high MICs to both antibiotics and for the first time C. difficile 
isolate with vancomycin MIC >1024 µg/ml was isolated.  Cluster and statistical analysis 
revealed that the percentage of metronidazole resistant isolates was greater than 
vancomycin resistant isolates in both patient populations examined, and there is a 
greater tendency for a C. difficile isolate to be metronidazole – or – vancomycin 
resistant in Kenya than Texas. PCR analysis of the vancomycin-resistant isolates 
revealed the presence of a vanA, gene responsible for vancomycin resistance in other 
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Gram-positive bacteria. Further studies will be necessary to uncover the mechanism of 
resistance. 
To determine the prevalence of metronidazole- and- vancomycin resistance in clinical 
isolates of C. difficile from Texas and Kenya, the stool samples were analyzed using C. 
difficile specific agar selective medium. The stool samples that contained C. difficile 
strains resistant to either or both antibiotics were grouped into three categories, Met-R, 
Van-R and Met-Van-R, and comprised of 33% of the Texas stool samples and 
unexpectedly 93.7% of the Kenya stool samples. These prevalence rates significantly 
exceed prior reports from other studies such as, the 2011 to 2014 longitudinal 
surveillance report from the US and Europe, which reported a low percent of both 
metronidazole and vancomycin resistance (28). The sudden increase in prevalence 
could be a result of an unexplored potential link between CDI treatment failure and 
antimicrobial resistance. CDI treatment failure has not been shown to have a 
relationship with antimicrobial resistance (4). A reduced 8 µg/ml fecal concentration of 
metronidazole may result in a simultaneous decrease of concentration that 
accompanied reduction of colonic inflammation (4). This concentration is high enough to 
kill susceptible C. difficile strains and low enough to be a sub-inhibitory concentration for 
resistant strains so that it could play a role in selecting and sustaining colonies with a 
gradually increase in their MICs (81). In addition, as the concentration decreases 
following cessation of metronidazole treatment, persistent spores could germinate into 
vegetative cells (4). What appears to be a gradual increase in the prevalence of 
metronidazole and vancomycin resistance from the previous (28) to the present 
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indicates gradual dissemination of both vancomycin and metronidazole resistant 
isolates in the community. 
One interesting finding from this study was that a greater number of the isolates were 
metronidazole resistant than vancomycin resistant. Although considerable variation in 
C. difficile resistance patterns has generally been observed, the percent of vancomycin 
resistance has been shown to exceed metronidazole resistance in most previous 
studies (30). However, in this study, the rate of metronidazole resistance exceeded that 
of vancomycin: 29.2% metronidazole and 26% vancomycin resistant isolates in Texas 
and 84.7% metronidazole and 67.3% vancomycin in the examined Kenya population. 
Conversely, previous published reports showed that 3.6% of stools from CDI patients in 
the US, contained C. difficile strains that are resistant to metronidazole and 17.9% to 
vancomycin (77). Similarly, prevalence rates of 0.11% and 2.29% were reported for 
metronidazole and vancomycin, respectively, in Europe (77).  Another study also 
reported that 94% of the C. difficile isolates collected from Iran were susceptible to 
metronidazole at 2 μg/ml and only 5.3% were vancomycin resistant (84). However, a 
study conducted in Israel reported 47% vancomycin and 18% metronidazole resistance 
(88). Interestingly, one study here in Texas reported 13.3% metronidazole resistance 
and 0% vancomycin resistance (89), which is consistent with our report, although no 
vancomycin resistance was isolated. The variation in resistance is probably as a result 
of geographical location, and local or national antibiotics treatment policies. It is 
noteworthy that, the hypervirulent strain (RT) 027 was consistently isolated in most 
metronidazole and vancomycin resistance studies (4, 30). Its emergence underscored 
the potential importance of antimicrobial resistance in spreading of epidemic C. difficile 
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clones. Eleven (11) out of twenty (20) resistant strains from a European antimicrobial 
surveillance study were ribotype 027 (77). 
To determine the predisposition of an isolate becoming resistant to either or both 
antibiotics in the two populations studied, Pearson’s statistical analysis was employed. 
The analysis indicated that there is a higher tendency for a C. difficile isolate to be 
metronidazole resistant in Kenya than Texas. This may be as a result of frequent self-
medication with metronidazole that occurs in Kenya. Unexpectedly, the tendency for 
vancomycin resistance is also higher in Kenya than Texas even though, there is no 
significant vancomycin treatment of CDI in Kenya. Both metronidazole and vancomycin 
resistance are more prevalent in Kenya than Texas. However, there was a greater 
number of highly vancomycin resistant isolates in the Texas samples than those from 
Kenya, suggesting that the reported inappropriate empirical treatment of CDI patients 
who do not meet the criteria for severe CDI may be responsible (15).     
To determine the level of antibiotic resistance in the isolated C. difficile strains, the E- 
test strip assay was used. Isolates from the three groups of resistance (Met-R, Van-R 
and Met-Van-R) were represented. Most of the metronidazole sensitive isolates (3 out 
of 4) became metronidazole resistant and even more (12 out of 15) vancomycin 
sensitive became resistant. This unanticipated change from sensitive to resistant 
suggests heterogenous resistance resulting from some C. difficile sensitive strains 
expressing resistance after freeze-thawing of stored samples. Previous reports have 
also shown a similar phenotypic change after frozen samples were thawed for analysis 
(4, 90). Also, a slow-growing metronidazole resistant sub-population of C. difficile have 
been observed after an extended incubation period of the E-test assay (4). This was 
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also observed in our study. Sub-population of the isolates grew colonies inside the zone 
of inhibition after a period. 
To further confirm the E-test determined MICs of the resistant isolates and to determine 
the MICs beyond the 256 µg/ml limit of the E-test strip used in this study, broth 
microdilution method was used. Eighty (80%) and 41% of vancomycin resistant isolates 
from Texas and Kenya, respectively, had vancomycin MIC >16 µg/ml, which is 
significantly higher than the currently reported maximum MIC 16 µg/ml (30). Whereas 
the proportion of the metronidazole resistant isolates with metronidazole MIC ˃ 256 
µg/ml (78), was 97.8% and 86.6% for Texas and Kenya respectively. It was not 
unexpected to isolate metronidazole-resistant isolates with significantly high MIC as 
sub-inhibitory concentration of metronidazole measured in the colon (0.8 to 24.2 µg/g) 
might play a role in selecting and sustaining colonies with a gradual increase in MICs 
(81). However, similar MIC levels in vancomycin-resistant isolate was unanticipated as 
the fecal concentration of vancomycin is high, range from 520 to 2200 µg/ml (82, 89). 
The observed high MIC could also be because of horizontal gene transfer from other 
Gram-positive bacteria possessing vancomycin resistance genes. The C. difficile 
genome (11%) contains mobile genetic element that includes antibiotics resistant 
genes. These could be transferred between different C. difficile strains or between C. 
difficile and other bacteria (30,90). High level of resistance in vancomycin-resistant 
Staphylococcus aureus was found to be a result of horizontal gene transfer from 
coinfecting vancomycin-resistant Enterococcus (91).  
The report of this study calls for attention to the significant percent of Texas and Kenyan 
patients (95%) who may not respond to metronidazole treatment and 80% and 41% of 
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Texas and Kenyan respectively, who may equally not respond to vancomycin treatment 
(Fig. 8). These are the percent of C. difficile isolates from patient stool samples with 
MICs higher than four times the currently prescribed dosage of metronidazole and 
vancomycin which is the maximum concentration of antibiotics that will effectively clear 
the bacteria from the system (93). The highest dosage of metronidazole currently 
prescribed is 500 mg (91, 92) and 125 mg for vancomycin (92). Use of metronidazole 
for long‐term chronic therapy or beyond the first recurrence of CDI is not recommended 
because of its potential cumulative neurotoxicity (54). Nephrotoxicity is also a potential 
serious side effect associated with high and prolong vancomycin therapy (92). As a 
result, an increase in dosage or prolonged therapy with either of the antibiotics is greatly 
discouraged. 
No correlation between toxin production and the levels of resistance was observed for 
the 20 isolates with different MICs selected from Texas and Kenya suggesting that 
different pathways control toxin production and antibiotics resistance. However, no 
measurable toxin production was recorded in the isolates that had grown poorly as it 
has been shown that toxin production in C. difficile is quorum sensing regulated (12) 
and so these experiments will be repeated with high level of growth for all the isolates. 
In this study, the effect of sub-inhibitory concentrations of vancomycin on biofilm 
formation showed no significant effect on the isolates with high resistance, intermediate 
resistance, and low resistance. On the contrary, a similar study that tested the effect of 
sub-inhibitory concentrations of metronidazole (not vancomycin) on biofilm formation 
in C. difficile strains (79) revealed a significant increase in biofilm formation when 
treated with metronidazole in the strains with reduced antibiotic susceptibility and 
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susceptible strain but their stable-resistant strain had no change in biofilm formation 
when the antibiotic was in the medium. Our experiment was performed using crystal 
violet assay which has limitations and this result could be improved with a more 
comprehensive assay. 
The recognized genes for vancomycin resistance include vanA, B, and D that are 
responsible for the biosynthesis D-alanine-D-lactate instead of the normal terminating 
precursor D-alanine-D-alanine. Vancomycin-resistant E. faecalis and E. faecium that 
possess vanA have been associated with inducible high level of resistance to 
vancomycin (MICs, ≥64 μg/ml). Initially vanB was believed to induce modest levels of 
vancomycin resistance (MICs, 32 to 64 μg/ml), however, recent reports revealed that 
vanB gene may afford a maximum resistant up to ≥1000 μg/ml (122).  vanC, E, G, and L 
are responsible for D-alanine-D-serine biosynthesis instead of normal D-ala-D-ala-
terminating precursors and are associated with low-level vancomycin resistance. This 
characterized low-level resistance to vancomycin have been found and well-studied in 
Staphylococcus aureus and Enterococcus spp (30, 94). To date, no functional 
vancomycin resistance genes have been identified in C. difficile (30). Since one of these 
listed nine genes is always expressed (30) in vancomycin resistant in other Gram-
positive bacteria, we decided to perform a PCR analysis using PCR primers for the nine 
genes to explore potential amplification of any of the genes in our isolates. Interesting, 
the vanA primer successfully amplified the expected 800bp fragment in all the resistant 
isolates tested. The vanA gene has been previously shown to mediate high level of 
resistance to vancomycin and it is possible that the observed high level of resistance in 
our isolates is related to the vanA gene. 
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 The vanA gene encodes the enzyme that synthesizes D-alanine-D-lactate and 
functions in conjunction with three other enzymes Van H, X and Y. The mechanism is 
well studied and defined in both Staphylococcus aureus and Enterococcus spp (30). To 
begin our studies of the vancomycin resistance mechanism in C. difficile, we will first 
attempt to identify the vanH X and Y genes in the genome of our vancomycin resistant 
isolates either by PCR or whole genome sequencing. The mechanism of vancomycin 
resistance may be different in the different C. difficile strains as a previous study has 
shown the diversity in the genome of different strains of C. difficile.  For instance, the 
hypervirulent strain (R20291) that encode both accessory gene regulator (agr1 and 
agr2) and the non-hypervirulent strain (630) encodes only agr1 (107). 
Multiple studies have investigated the diversity in the genome of C. difficile, however, 
this is the first time the vanA gene is identified in vancomycin-resistant C. difficile 
isolates. The PCR products amplified using the primers were directly sequenced and 
compared with vanA gene of E. faecieum, the observed differences in the 5’ end of the 
sequence alignment strongly suggest poor amplification of some of the PCR products 
resulting in poor sequence that impeded the data evaluation. As a result, the PCR 
products were cloned into a vector, transformed and the clones were sequenced. They 
gave better result (13).  
In the future, the potential relationship between the degree of resistance and the colony 
appearance (sizes or shape) will be explored. Each plate containing stool samples with 
viable C. difficile colonies was analyzed and the different sizes and shapes of colonies 
recorded. Some of the colonies possessed irregular, Webb-like shapes or smooth 
edges. The study of colony morphology is important, as other studies have shown that 
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the surface layer (S-layer), is responsible for bacteria adhesion to host cells and that a 
mutation in one of the cysteine proteases involved in assembly of S-layer, resulted in 
the inability to retain a specific cell wall protein leading to altered cell morphology (86). 
Another study that compared an assay for selective and differential C. difficile isolation 
from feces showed that colony size enables possible identification within 24 hours (87).   
In summary, the data reported here, established the prevalence of metronidazole- and-
vancomycin resistance C. difficile isolates from Texas and Kenyan CDI patients, 
determined the level of resistance of each of the isolates, reported a high vancomycin 
MIC greater than the currently reported and suggest for the first time the mechanism 
responsible for vancomycin resistance. 
 
Summary and Perspective 
The goal of the thesis was to establish the prevalence of metronidazole- and 
vancomycin-resistance in C. difficile in two different populations and also to uncover the 
potential resistance mechanisms involved. We isolated and characterized 
metronidazole- and- vancomycin resistant isolates from stool samples from both Texas 
and Kenya and analyzed their prevalence according to the location and the tendency of 
acquiring each resistance with respect to location. C. difficile resistance to both 
antibiotics is prevalent in both Texas and Kenya. Interestingly higher resistance to both 
antibiotics is prevalent in Kenya. 
Analysis of the degree of resistance of the isolates revealed relatively high MICs in the 
two the populations. The two methods used for MIC determination (the E-test strip and 
broth microdilution methods), were compared. The E-test method had an agreement of 
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˃90% in comparison to broth microdilution method. There is a significantly high level of 
metronidazole-resistance in both populations when compared to vancomycin. The 
degree of vancomycin resistance is more spread across all levels of resistance although 
a high proportion had a high degree of resistance with ˃256 µg/ml. On the other hand, a 
relatively significant percent of metronidazole resistance isolates is highly resistant. 
Three distinct groups were identified after MIC determination, the low resistance, 
intermediate resistance, and high resistance. These three groups will be used for further 
analysis. In the future, whole genome sequence analysis will allow a comparison 
between the three groups and analysis of gene expression can also be used. This 
analysis will help to uncover the resistance mechanism and possibly be useful in the 
identification of a small molecule inhibitor as an alternative therapy. 
 Colonies were classified in order to explore potential relationship between the degrees 
of resistance or etiology to the sizes of the different colonies. Viable colonies had 
different sizes with some possessing irregular edges, Webb-like shapes and smooth 
round edges. Further studies will explore these phenotypes. The study of colony 
morphology is important, as other studies have shown that the surface layer (S-layer), is 
responsible for bacteria adhesion to host cells and that a mutation in one of the cysteine 
proteases involved in assembly of S-layer, resulted in the inability to retain a specific 
cell wall protein leading to altered cell morphology (113). Another study that compared 
an assay for selective and differential C. difficile isolation from feces showed that size of 
colony enables possible identification within 24 hours (114).   
Further analysis is required to examine the spore formation ability of the different 
colonies, toxin production and explore their relationship with antibiotic resistance.   
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Our hypothesis that sub-inhibitory concentration of vancomycin will induce more biofilm 
formation in the reduced susceptible and intermediate isolates, but not high resistant 
was proven false, although as expected, the high resistant isolates that may not need 
biofilm as a defense mechanism in the presence of vancomycin had minimal biofilm 
formation. Further analysis is recommended in the biofilm analysis with a more accurate 
assay or technique. 
 
Future Experiments 
1. A study to isolate Enterococci species from the same stool samples containing C. 
difficile isolates with high vancomycin-resistance in order to analyze and 
compare the vanA gene is recommended.  
2. VanA-type resistance is mediated by transposon Tn1546 (20). A whole genome 
sequence analysis is recommended to determine if the same transposon also 
mediates the vanA gene in C. difficile and to determine whether the resistance is 
due to a genomic mutation or plasmid-encoded. 
3. A detailed study of the pathway that mediates vanA resistance is suggested to 
develop a novel target, such as small nonantibiotics molecules that will address 
the high level of resistance. 
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